{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:54:57Z","timestamp":1771232097364,"version":"3.50.1"},"reference-count":81,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005864","name":"NACOSTI","doi-asserted-by":"publisher","award":["91530969"],"award-info":[{"award-number":["91530969"]}],"id":[{"id":"10.13039\/501100005864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57139945"],"award-info":[{"award-number":["57139945"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites.<\/jats:p>","DOI":"10.3390\/microorganisms6030073","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T02:10:11Z","timestamp":1532052611000},"page":"73","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antiviral Compounds from Myxobacteria"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-8834","authenticated-orcid":false,"given":"Lucky S.","family":"Mulwa","sequence":"first","affiliation":[{"name":"Department of Microbial Drugs, Helmholtz Centre for Infection Research and German Centre for Infectio Research (DZIF), Partner Site Hannover\/Braunschweig, Inhoffenstrasse 7, 38124 Braunschweig, Germany"},{"name":"Department of Microbial Strain Collection (MISG), Helmholtz Centre for Infection Research (HZI), Inhoffenstrasse 7, 38124 Braunschweig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-8671","authenticated-orcid":false,"given":"Marc","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Microbial Drugs, Helmholtz Centre for Infection Research and German Centre for Infectio Research (DZIF), Partner Site Hannover\/Braunschweig, Inhoffenstrasse 7, 38124 Braunschweig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"ref_1","first-page":"35","article-title":"Emergence and spread of antimicrobial resistance: Recent insights from bacterial population genomics","volume":"Volume 398","author":"Stadler","year":"2017","journal-title":"How to Overcome the Antibiotic Crisis\u2014Facts, Challenges, Technologies & Future Perspective"},{"key":"ref_2","first-page":"1","article-title":"Current Landscape of Antiviral Drug Discovery","volume":"5","author":"Blair","year":"2016","journal-title":"F1000 Rev."},{"key":"ref_3","unstructured":"World Health Organization (2018, May 18). Antimicrobial resistance. Available online: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/INF.0000000000001597","article-title":"High prevalence of Abacavir-associated L74V\/I mutations in Kenyan children failing antiretroviral therapy","volume":"36","author":"Dziuban","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_5","unstructured":"U.S. Food & Drug Administration (2018, May 22). Antiretroviral Drugs Used in the Treatment of HIV Infection, Available online: https:\/\/www.fda.gov\/ForPatients\/Illness\/HIVAIDS\/Treatment\/ucm118915.htm."},{"key":"ref_6","unstructured":"National Institute of Allergy and Infectious Disease (2018, May 22). Drugs That Fight HIV-1, Available online: https:\/\/aidsinfo.nih.gov\/contentfiles\/upload\/HIV_Pill_Brochure.pdf."},{"key":"ref_7","unstructured":"DailyMed (2018, May 22). Drug Listing Certification, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm."},{"key":"ref_8","first-page":"1443","article-title":"Common adverse effects of antiretroviral therapy for HIV disease","volume":"83","author":"Reust","year":"2011","journal-title":"Am. Fam. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/jmbi.1994.1665","article-title":"Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance","volume":"243","author":"Tantillo","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against Hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jhep.2015.06.002","article-title":"Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity","volume":"63","author":"Koutsoudakis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1039\/C6NP00106H","article-title":"Natural products from myxobacteria: Novel metabolites and bioactivities","volume":"34","author":"Herrmann","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1002\/anie.201705913","article-title":"Discovery and total synthesis of natural cystobactamid derivatives with superior activity against Gram-negative pathogens","volume":"56","author":"Testolin","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7164\/antibiotics.47.23","article-title":"The soraphens: A family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria)","volume":"47","author":"Gerth","year":"1994","journal-title":"J. Antibiot."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.jim.7000025","article-title":"Myxobacteria, producers of novel bioactive substances","volume":"27","author":"Reichenbach","year":"2001","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbiotec.2003.07.015","article-title":"Myxobacteria: Proficient producers of novel natural products with various biological activities\u2014Past and future biotechnological aspects with the focus on the genus Sorangium","volume":"106","author":"Gerth","year":"2003","journal-title":"J. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1574-6976.2000.tb00548.x","article-title":"Biology and global distribution of myxobacteria in soils","volume":"24","author":"Dawid","year":"2000","journal-title":"FEMS Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1099\/ijsem.0.002569","article-title":"Nannocystis konarekensis sp. nov., a novel myxobacterium from an Iranian desert","volume":"68","author":"Mohr","year":"2018","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1039\/b901287g","article-title":"Myxobacteria\u2014\u2018Microbial factories\u2019 for the production of bioactive secondary metabolites","volume":"5","author":"Wenzel","year":"2009","journal-title":"Mol. BioSyst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1039\/c001260m","article-title":"Myxobacterial secondary metabolites: Bioactivities and modes-of-action","volume":"27","author":"Weissman","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3762\/bjoc.12.58","article-title":"Antibiotics from predatory bacteria","volume":"12","author":"Korp","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15200","DOI":"10.1073\/pnas.0607335103","article-title":"Evolution of sensory complexity recorded in a myxobacterial genome","volume":"103","author":"Goldman","year":"2006","journal-title":"Prod. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1039\/b817073h","article-title":"The impact of genomics on the exploitation of the myxobacterial secondary metabolome","volume":"26","author":"Wenzel","year":"2009","journal-title":"Nat. Prod. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3762\/bjoc.12.96","article-title":"Marine-derived myxobacteria of the suborder Nannocystineae: An underexplored source of structurally intriguing and biologically active metabolites","volume":"12","author":"Hufendiek","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nbt1354","article-title":"Complete genome sequence of the myxobacterium Sorangium cellulosum","volume":"25","author":"Schneiker","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1039\/c4np00011k","article-title":"Antibiotics from myxobacteria","volume":"31","author":"Lohr","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/1439-7633(20020703)3:7<619::AID-CBIC619>3.0.CO;2-9","article-title":"Big effects from small changes: Possible ways to explore nature\u2019s chemical diversity","volume":"3","author":"Bode","year":"2002","journal-title":"ChemBioChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000445852","article-title":"Human Immunodeficiency Virus (HIV)","volume":"43","author":"Seitz","year":"2016","journal-title":"Transfus. Med. Hemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1021\/acs.jmedchem.5b00709","article-title":"Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity","volume":"58","author":"Curreli","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1021\/jm990154t","article-title":"Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the Human Immunodeficiency Virus type 1","volume":"42","author":"Asim","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Martinez, J.P., Hinkelmann, B., Fleta-Soriano, E., Steinmetz, H., Jansen, R., Diez, J., Frank, R., Sasse, F., and Meyerhans, A. (2013). Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. Microb. Cell Fact., 12.","DOI":"10.1186\/1475-2859-12-85"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1002\/chem.201100851","article-title":"Sulfangolids, macrolide sulfate esters from Sorangium cellulosum","volume":"18","author":"Zander","year":"2012","journal-title":"Chem. Eur. J."},{"key":"ref_33","unstructured":"(2018, July 10). Available online: https:\/\/scifinder.cas.org\/scifinder\/view\/scifinder\/scifinderExplore.jsf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.molcel.2004.11.034","article-title":"A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product","volume":"16","author":"Shen","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_35","first-page":"3344","article-title":"Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity","volume":"57","author":"Sasse","year":"1997","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: Mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1158\/1078-0432.CCR-05-0740","article-title":"In vivo evaluation of Ixabepilone (BMS247550), A novel epothilone B derivative, against pediatric cancer models","volume":"11","author":"Peterson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/cbic.201100635","article-title":"The myxobacterial compounds spirangien A and spirangien M522 are potent inhibitors of IL-8 expression","volume":"13","author":"Reboll","year":"2012","journal-title":"ChemBioChem"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/095632029200300401","article-title":"Three new potent HIV-1 inhibitors from myxobacteria","volume":"3","author":"Jurkliewicz","year":"1992","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jlac.1992199201112","article-title":"Phenalamide, neue HIV-1-Inhibitoren aus Myxococcus stipitatus Mx s40","volume":"1992","author":"Forche","year":"1992","journal-title":"Liebigs Ann. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1099\/ijsem.0.000813","article-title":"Aetherobacter fasciculatus gen. nov., sp. nov. and Aetherobacter rufus sp. nov., novel myxobacteria with promising biotechnological applications","volume":"66","author":"Garcia","year":"2016","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/ol3011002","article-title":"Aetheramides A and B, potent HIV-inhibitory depsipeptides from a Myxobacterium of the new genus \u201cAetherobacter\u201d","volume":"14","author":"Plaza","year":"2012","journal-title":"Org. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7164\/antibiotics.48.973","article-title":"Ratjadon: A new antifungal compound from Sorangium cellulosum (Myxobacteria) Production, physico-chemical and biological properties","volume":"48","author":"Gerth","year":"1995","journal-title":"J. Antibiot."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2859-13-17","article-title":"The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev\/CRM1-mediated nuclear export pathway","volume":"13","author":"Martinez","year":"2014","journal-title":"Microb. Cell Fact."},{"key":"ref_45","unstructured":"ICTV (2018, April 30). Taxonomy. Available online: https:\/\/talk.ictvonline.org\/taxonomy\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/jvi.64.3.1079-1085.1990","article-title":"Cell surface expression of Human Cytomegalovirus (HCMV): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J. Virol."},{"key":"ref_47","first-page":"497","article-title":"Chronic Intrauterine and Perinatal Infections","volume":"Volume 3","author":"Galassov","year":"1990","journal-title":"Antiviral Agents and Viral Diseases of Man"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/095632029901000501","article-title":"Human cytomegalovirus: Challenges opportunities and new drug development","volume":"10","author":"Field","year":"1999","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/13543776.10.2.165","article-title":"Novel agents for the treatment of human cytomegalovirus infection","volume":"10","author":"Castro","year":"2000","journal-title":"Exp. Opin. Ther. Pat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of Cidofovir into DNA by Human Cytomegalovirus DNA polymerase on DNA elongation","volume":"24","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/173.3.523","article-title":"Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leucocytes of patients with fatal disseminated CMV disease","volume":"173","author":"Boivin","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.1996.5231066.x","article-title":"Comparison of benzimidazole nucleosides ganciclovir on the in vitro proliferation and colony formation of human marrow progenitor cells","volume":"93","author":"Nassir","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transpl."},{"key":"ref_54","unstructured":"NEJM Journal Watch (2018, June 17). Letermovir Approved to Prevent CMV Infection and Disease in Transplant Patients. Available online: https:\/\/www.jwatch.org\/na45554\/2017\/12\/07\/letermovir-approved-prevent-cmv-infection-and-disease."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/np500909b","article-title":"Myxochelins Target Human 5-Lipoxygenase","volume":"78","author":"Schieferdecker","year":"2015","journal-title":"J. Nat. Prod."},{"key":"ref_56","first-page":"229","article-title":"Medical applications of siderophores","volume":"8","author":"Nagoba","year":"2011","journal-title":"Eur. J. Gen. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ja.2006.93","article-title":"Absolute configuration and antitumor activity of myxochelin a produced by Nonomuraea pusilla TP-A0861","volume":"59","author":"Miyanaga","year":"2006","journal-title":"J. Antibiot."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/cbic.201500446","article-title":"Harnessing enzymatic promiscuity in myxochelins biosynthesis for the production of 5-lipoxygenase inhibitors","volume":"16","author":"Korp","year":"2015","journal-title":"ChemBioChem"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cmdc.201600536","article-title":"Myxochelin-inspired 5-lipoxygenase inhibitors: Synthesis and biological evaluation","volume":"12","author":"Schieferdecker","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.bmc.2009.02.040","article-title":"Synthesis and evaluation of myxochelins analogues as antimetastatic agents","volume":"17","author":"Miyanga","year":"2009","journal-title":"Biol. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ambrosi, H.D., Hartmann, V., Pistorius, D., Reissbrodt, R., and Trowitzsch-Kienast, W. (1998). Myxochelins B, C, D, E and F: A new structural principle for powerful siderophores imitating Nature. Eur. J. Org. Chem., 541\u2013551.","DOI":"10.1002\/(SICI)1099-0690(199803)1998:3<541::AID-EJOC541>3.0.CO;2-A"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cbic.200400206","article-title":"Novel insights into siderophore formation in myxobacteria","volume":"6","author":"Gaitatzis","year":"2005","journal-title":"Chembiochem"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/ol501826a","article-title":"Hyalachelins A\u2013C, Unusual Siderophores Isolated from the terrestrial Myxobacterium Hyalangium minutum","volume":"16","author":"Nadmid","year":"2014","journal-title":"Org. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7164\/antibiotics.45.147","article-title":"Nannochelins A, B and C, new iron-chelating compounds from Nannocystis exedens (myxobacteria) production, isolation, physico-chemical and biological properties","volume":"45","author":"Kunze","year":"1991","journal-title":"J. Antibiot."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1007\/s11356-015-4294-0","article-title":"Microbial siderophores and their potential applications: A review","volume":"23","author":"Saha","year":"2016","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_66","unstructured":"World Health Organization (2018, May 05). Ebola virus Disease. Available online: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/ebola-virus-disease."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2016.05.017","article-title":"Identification of inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library","volume":"132","author":"Beck","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.7164\/antibiotics.48.1262","article-title":"New antifungal and cytostatic depsipeptides from Chondromyces crocatus (Myxobacteria). Production, physico-chemical and biological Properties","volume":"48","author":"Kunze","year":"1995","journal-title":"J. Antibiot."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0167-7799(88)90100-X","article-title":"Myxobacteria: A source of new antibiotics","volume":"6","author":"Reichenbach","year":"1988","journal-title":"Trends Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/anie.201106435","article-title":"Isolation and total synthesis of icumazoles and noricumazoles\u2014Antifungal antibiotics and cation-channel blockers from Sorangium cellulosum","volume":"51","author":"Barbier","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7164\/antibiotics.53.879","article-title":"Tubulysins, new cytostatic peptides from Myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties","volume":"53","author":"Sasse","year":"2000","journal-title":"J. Antibiot."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_73","unstructured":"World Health Organization (2018, May 10). Hepatitis C. Available online: http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Mulwa, L., Jansen, R., Praditya, D., Mohr, K., Wink, J., Steinmann, E., and Stadler, M. (2018). Six heterocyclic metabolites from the Myxobacterium Labilithrix luteola. Molecules, 23.","DOI":"10.3390\/molecules23030542"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jlac.1993199301161","article-title":"Isolation and structure elucidation of soraphen A1\u03b1, a novel antifungal macrolide from Sorangium cellulosum","volume":"1993","author":"Bedorf","year":"1993","journal-title":"Liebigs Ann. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/acsinfecdis.5b00019","article-title":"Soraphen A: A probe for investigating the role of de novo lipogenesis during viral infection","volume":"1","author":"Singaravelu","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.antiviral.2010.12.005","article-title":"Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity","volume":"89","author":"Gentzsch","year":"2011","journal-title":"Antiviral Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3762\/bjoc.14.132","article-title":"Lanyamycin, a macrolide antibiotic from Sorangium cellulosum, strain Soce 481 (Myxobacteria)","volume":"14","author":"Mulwa","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1152\/ajplung.00011.2014","article-title":"Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1","volume":"308","author":"Yeganeh","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41467-018-03184-1","article-title":"Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria","volume":"9","author":"Hoffmann","year":"2018","journal-title":"Nat. Commum."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/6\/3\/73\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:13:01Z","timestamp":1760195581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/6\/3\/73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["microorganisms6030073"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms6030073","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}